Methylprednisolone Treatment of Friedreich Ataxia
Open-label Pilot Study of Methylprednisolone for the Treatment of Patients With Friedreich Ataxia (FRDA)
Sponsor: Children's Hospital of Philadelphia
This EARLY_PHASE1 trial investigates Friedreich Ataxia and is currently completed. Children's Hospital of Philadelphia leads this study, which shows 10 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Apr 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Completed EARLY_PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Completed EARLY_PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Oct 2020 [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Jul 2017 — Jan 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jul 2017 [monthly]
Recruiting EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting Phase 0
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Hospital of Philadelphia
- Friedreich's Ataxia Research Alliance
For direct contact, visit the study record on ClinicalTrials.gov .